Get the latest news on HUMBL stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on HMBL performance

Latest HUMBL Stock News | OTC:HMBL | Benzinga

HUMBL Inc is a digital commerce company. It operates a platform to connect consumers, businesses, and governments in the digital economy. HUMBL provides simple tools and packaging for complex new technologies such as blockchain, in the same way that previous cycles of e-commerce and the cloud were more simply packaged by companies such as Facebook, Apple, Amazon and Netflix over the past several decades. The company's segment includes Consumer and Commercial. It generates maximum revenue from the Consumer segment. They account for revenues based on the verticals in which they were earned, the three principal verticals being HUMBL Wallet, and HUMBL Marketplace, HBS.

cannabis shacking hands (lindsayfox and Tusumi by Pixabay)(7)

Cannabis

News

Movers & Shakers

AFCG

CSE:HMBL

CSE:IAN

CSE:MMEN

CSE:MRMD

CWBHF

CWEB

FLGC

HMBL

HUMBF

ITHUF

KAVL

MMNFF

MRMD

PCLOF

TSXV:PCLO

UNRIVALED BRANDS INC by Unrivaled Brands, Inc.

UNRV

Top Cannabis Industry Leaders Who Took The Reins In 2023

HUMBL Inc

Macro Economic Events

Economics

Federal Reserve

Fed's Hammack Says Discount Window Is A 'Very Helpful Tool' For Banks When Needed

DA Davidson analyst Gil Luria maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Neutral and maintains $135 price target.

Price Target

Analyst Ratings

NVDA

DA Davidson Maintains Neutral on NVIDIA, Maintains $135 Price Target

Fed's Hammack Says Regulation Works Best In Form Of Suggestions Rather Than Punishments

Salesforce Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) shares tanked in early trading on Thursday, after the company reported <a href="https://www.benzinga.com/news/earnings/25/02/43991325/salesforce-shares-sink-after-q4-revenues-miss-estimates-weak-fy26-guidance-details">its fourth-quarter results</a>.
The results came in amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
<h1 class="wp-block-heading">Needham On Salesforce</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587635595064ed000140010c/scott-berg">Analyst Scott Berg</a> reaffirmed a Buy rating and price target of $400.
Salesforce reported fourth-quarter revenue of $10 billion and $1.75 per share, Berg said in a note. Total revenue grew by 7.6% year-on-year, 9% in constant currency terms, with subscription revenue growing 8%, he added.
CRPO (current remaining performance obligation) grew 9.4% year-on-year to $30.2 billion, benefitting from "strength in Data Cloud and AI along with early renewals," the analyst wrote. Management guided to revenue in the range of $40.5 billion to $40.9 billion for fiscal 2026, representing 7.4% growth at the midpoint, well below consensus of 9.2% growth to $41.375 billion, he further stated.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
<h1 class="wp-block-heading">JPMorgan On Salesforce</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d5296ab85e930001416e5a/mark-murphy">Analyst </a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d5296ab85e930001416e5a/mark-murphy">Mark Murphy</a> reiterated an Overweight rating and price target of $380.
Salesforce's total revenue came in below expectation in U.S. dollar terms but ahead in constant currency terms, while Subscription &amp; Support revenue was below on a USD basis and in-line in constant currency terms, Murphy said. The fourth-quarter results were "encouraging, with cRPO CC growth accelerating from 10% in Q3 to 11% in Q4," he added.
Management's cRPO growth guidance in constant currency terms came in ahead of Street expectations, which is "important as cRPO is viewed as the key leading indicator for Salesforce," the analyst wrote. The revenue guidance miss is "relatively innocuous," while the Subscription &amp; Support revenue growth guidance is only below consensus by around 0.5%, he further stated.
<h1 class="wp-block-heading">Guggenheim Securities On Salesforce</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587f78d077f9dd000126ef0f/john-difucci">Analyst John DiFucci</a> maintained a Sell rating and price target of $247.
Salesforce's total revenue of $9.993 billion missed consensus estimate of $10.044 billion, "which was partially driven by incremental FX headwinds, DiFucci said. Subscription revenue of $9.451 billion came in 70 basis points below Street estimates, while Professional Services revenue beat expectations by 3%, he added.
While management's total revenue guidance for the first quarter appears conservative, their full-year guidance calls for 32% new ACV (annual contract value) growth, the analyst stated. "CRM hasn't seen that level of New ACV growth since 2017 when it was a very different company (i.e., much better positioned)," he further wrote.
CRM Price Action: Shares of Salesforce had declined by 1.17% to $303.74 at the time of publication on Thursday.
Read More: <a href="https://www.benzinga.com/general/market-summary/25/02/43875446/walmarts-ai-use-cases-surge-amid-strong-q4-even-as-company-forecasts-weaker-2026"> </a> • <a href="https://www.benzinga.com/general/market-summary/25/02/43875446/walmarts-ai-use-cases-surge-amid-strong-q4-even-as-company-forecasts-weaker-2026">Salesforce Looks Beyond CRM, Bets Big On &#8216;Digital Labor Revolution:&#8217; CEO Marc Benioff Predicts A $12 Trillion Market, Says It Is &#8216;Much Bigger Than Software&#8217;</a>
 Photo: Gonzo via Shutterstock

Analyst Color

Earnings

Reiteration

Movers

Trading Ideas

Salesforce's Shares Drop On Missed FY Guidance, Analyst Recommends Focus On Bookings

WIIM

ANET

BNZI

CEVA

DELL

MOBBW

MPWR

MRVL

Next Technology Holding Inc. - Ordinary Shares

NXTT

PCLA

PONY

SLNH

SMCI

SYTA

VNET

Shares of companies within the broader tech sector are trading lower in sympathy with Nvidia, which reversed amid a possible selloff after reporting its Q4 financial results.

DA Davidson analyst Matthew Summerville maintains Diebold Nixdorf (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBD#NYSE">DBD</a>) with a Buy and raises the price target from $65 to $80.

DA Davidson Maintains Buy on Diebold Nixdorf, Raises Price Target to $80

DA Davidson analyst Gil Luria maintains C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) with a Neutral and lowers the price target from $40 to $25.

DA Davidson Maintains Neutral on C3.ai, Lowers Price Target to $25

Whales with a lot of money to spend have taken a noticeably bullish stance on Merck &amp; Co.
Looking at options history for Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 66% of the investors opened trades with bullish expectations and 22% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $69,435 and 7, calls, for a total amount of $1,203,898.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $85.0 to $95.0 for Merck &amp; Co during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Merck &amp; Co stands at 8273.17, with a total volume reaching 10,621.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Merck &amp; Co, situated within the strike price corridor from $85.0 to $95.0, throughout the last 30 days.
<h3>Merck &amp; Co 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740681954_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$3.75</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$90.00</td>
<td>$443.5K</td>
<td>12.3K</td>
<td>2.5K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$90.00</td>
<td>$351.0K</td>
<td>12.3K</td>
<td>1.2K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.35</td>
<td>$2.15</td>
<td>$2.35</td>
<td>$90.00</td>
<td>$234.5K</td>
<td>10.7K</td>
<td>2.0K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.73</td>
<td>$1.7</td>
<td>$1.72</td>
<td>$95.00</td>
<td>$49.3K</td>
<td>6.3K</td>
<td>823</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$11.6</td>
<td>$11.25</td>
<td>$11.6</td>
<td>$85.00</td>
<td>$46.4K</td>
<td>307</td>
<td>20</td>
</tr>
</tbody>
</table>

<h3>About Merck &amp; Co</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Following our analysis of the options activities associated with Merck &amp; Co, we pivot to a closer look at the company's own performance.
<h3>Where Is Merck &amp; Co Standing Right Now?</h3>
<ul>
<li>With a trading volume of 4,348,312, the price of MRK is up by 0.87%, reaching $90.16.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 56 days from now.</li>
</ul>
<h3>Expert Opinions on Merck &amp; Co</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $108.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Merck &amp; Co, maintaining a target price of $115. 
&#x2A; In a cautious move, an analyst from Deutsche Bank downgraded its rating to Hold, setting a price target of $105. 
&#x2A; Maintaining their stance, an analyst from BMO Capital continues to hold a Market Perform rating for Merck &amp; Co, targeting a price of $96. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Merck &amp; Co with a target price of $112. 
&#x2A; An analyst from Guggenheim persists with their Buy rating on Merck &amp; Co, maintaining a target price of $115. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Merck &amp; Co options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

Decoding Merck & Co's Options Activity: What's the Big Picture?

Whales with a lot of money to spend have taken a noticeably bullish stance on Twilio.
Looking at options history for Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 75% of the investors opened trades with bullish expectations and 12% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $69,250 and 6, calls, for a total amount of $263,385.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $105.0 to $135.0 for Twilio during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Twilio's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Twilio's substantial trades, within a strike price spectrum from $105.0 to $135.0 over the preceding 30 days.
<h3>Twilio Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740681949_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TWLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.76</td>
<td>$2.53</td>
<td>$2.77</td>
<td>$135.00</td>
<td>$110.8K</td>
<td align="right">445</td>
<td align="right">420</td>
</tr>
<tr>
<td>TWLO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$4.3</td>
<td>$4.15</td>
<td>$4.3</td>
<td>$120.00</td>
<td>$42.9K</td>
<td align="right">62</td>
<td align="right">101</td>
</tr>
<tr>
<td>TWLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$4.55</td>
<td>$4.45</td>
<td>$4.55</td>
<td>$125.00</td>
<td>$34.1K</td>
<td align="right">703</td>
<td align="right">77</td>
</tr>
<tr>
<td>TWLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.75</td>
<td>$22.2</td>
<td>$22.6</td>
<td>$120.00</td>
<td>$33.9K</td>
<td align="right">177</td>
<td align="right">17</td>
</tr>
<tr>
<td>TWLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/28/25</td>
<td>$6.35</td>
<td>$6.1</td>
<td>$6.2</td>
<td>$120.00</td>
<td>$31.0K</td>
<td align="right">374</td>
<td align="right">51</td>
</tr>
</tbody>
</table>

<h3>About Twilio</h3>
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
After a thorough review of the options trading surrounding Twilio, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Twilio's Current Market Status</h3>
<ul>
<li>Trading volume stands at 879,376, with TWLO's price up by 1.43%, positioned at $120.92.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 68 days.</li>
</ul>
<h3>What The Experts Say On Twilio</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $153.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Twilio, which currently sits at a price target of $175. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Hold rating on Twilio with a target price of $145. 
&#x2A; Maintaining their stance, an analyst from Tigress Financial continues to hold a Buy rating for Twilio, targeting a price of $170. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Twilio, targeting a price of $140. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Hold rating on Twilio with a target price of $135. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Twilio, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

TWLO

What the Options Market Tells Us About Twilio

Investors with a lot of money to spend have taken a bullish stance on General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GD, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for General Dynamics.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 25%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $60,000, and 7, calls, for a total amount of $675,699.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $200.0 to $220.0 for General Dynamics over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for General Dynamics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of General Dynamics's whale activity within a strike price range from $200.0 to $220.0 in the last 30 days. 
<h3>General Dynamics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740681944_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$43.7</td>
<td>$43.3</td>
<td>$43.7</td>
<td>$220.00</td>
<td>$231.6K</td>
<td align="right">146</td>
<td align="right">60</td>
</tr>
<tr>
<td>GD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$45.1</td>
<td>$43.6</td>
<td>$43.8</td>
<td>$220.00</td>
<td>$175.2K</td>
<td align="right">146</td>
<td align="right">139</td>
</tr>
<tr>
<td>GD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$45.2</td>
<td>$42.5</td>
<td>$44.11</td>
<td>$220.00</td>
<td>$66.1K</td>
<td align="right">146</td>
<td align="right">77</td>
</tr>
<tr>
<td>GD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$14.0</td>
<td>$12.0</td>
<td>$12.0</td>
<td>$220.00</td>
<td>$60.0K</td>
<td align="right">30</td>
<td align="right">50</td>
</tr>
<tr>
<td>GD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$61.0</td>
<td>$59.4</td>
<td>$59.8</td>
<td>$200.00</td>
<td>$59.8K</td>
<td align="right">71</td>
<td align="right">12</td>
</tr>
</tbody>
</table>

<h3>About General Dynamics</h3>
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, marine, combat systems, and technology. General Dynamics' aerospace segment manufactures Gulfstream business jets and operates a global aircraft servicing operation. Combat systems produces land-based combat vehicles such as the M1 Abrams tank and Stryker armored personnel carrier, as well as munitions. The marine segment builds and services nuclear-powered submarines, destroyers, and other ships. The technologies segment contains two main units: an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computing, intelligence, surveillance, and reconnaissance capabilities to the military.
<h3>Where Is General Dynamics Standing Right Now?</h3>
<ul>
<li>With a trading volume of 547,640, the price of GD is up by 0.91%, reaching $251.51.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 55 days from now.</li>
</ul>
<h3>What The Experts Say On General Dynamics</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $284.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on General Dynamics, which currently sits at a price target of $335. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on General Dynamics, which currently sits at a price target of $284. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on General Dynamics with a target price of $276. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on General Dynamics with a target price of $244. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on General Dynamics, which currently sits at a price target of $285. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for General Dynamics with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

General Dynamics's Options: A Look at What the Big Money is Thinking

Needham analyst Tom Nikic reiterated the Hold rating on Steven Madden, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>).
Yesterday, the company reported&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43977589/steven-madden-q4-performance-beats-expectations-but-ceo-cautions-about-2025-profit-impact-from-tariff-headwinds" rel="noreferrer noopener">fourth-quarter&nbsp;2024 financial results</a>.
It clocked a fourth-quarter adjusted EPS of 55 cents,&nbsp;beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">Wall Street View of 53 cents</a>. Quarterly revenues of&nbsp;$582.32 million&nbsp;increased&nbsp;12.0%&nbsp;year over year, surpassing the <a target="_blank" href="https://www.benzinga.com/quote/SHOO/analyst-ratings" rel="noreferrer noopener">analyst consensus of&nbsp;$548.50 million.</a>
The analyst mentioned that the fourth quarter earnings call reflected caution, citing the ongoing impact of tariffs, struggles in the accessories business, and a decline in consumer sentiment, with the operating environment remaining challenging.
Also Read: <a target="_blank" href="http://benzinga.com/25/02/44011754/china-us-military-talks-resume-amid-de-escalation-hopes-litecoin-avalanche-defy-crypto-slump-nvidia-stock-sees-modest-pre-market-gain-despite-strong-earnings-top-headlines-while-the-us-slept" rel="noreferrer noopener">China-US Military Talks Resume Amid De-Escalation Hopes; Litecoin, Avalanche Defy Crypto Slump; Nvidia Stock Sees Modest Pre-Market Gain Despite Strong Earnings – Top Headlines While The U.S. Slept</a>
Nikic noted that the company is shifting its sourcing away from China, aiming for a low-40% reliance by November 2025, but anticipates tariff impacts starting in the first quarter.
Mitigation efforts are expected to take time, with any meaningful effects not likely until mid-2025 or 2026.
Additionally, the analyst supposed that gross margins could be adversely affected by at least 200 basis points.
Nikic highlighted that while the newly acquired Kurt Geiger brand still relies heavily on China for production, its U.S. exposure is lower, thus limiting the tariff impact compared to the core Steve Madden brand.
Management sees growth potential in expanding the brand's reach, particularly in APAC, and expects strong international growth, building on the 12% rise in the fourth quarter.
The Kurt Geiger brand is anticipated to grow in double digits this year, with plans to improve EBIT margins as synergies and tariff mitigation strategies take effect, the analyst adds.
Price Action: SHOO shares are trading lower by 4.25% to $33.36 at last check On Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44004387/hormels-q1-earnings-fall-short-of-estimates-amid-lower-margins" target="_blank" rel="noreferrer noopener">Hormel Foods Q1 Earnings: Organic Sales Edge Higher, EPS Misses, FY25 Outlook Intact And More</a></li>
</ul>
Photo by DCStockPhotography via Shutterstock.

Equities

General

SHOO

Steve Madden Faces Looming Margin Pressure And Tariff Headwinds, Analyst Predicts Tough Road Ahead

DA Davidson analyst Linda Bolton Weiser maintains Interparfums (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NASDAQ">IPAR</a>) with a Buy and raises the price target from $163 to $170.

IPAR

DA Davidson Maintains Buy on Interparfums, Raises Price Target to $170

Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.
Pursuant to the closing of a Securities Purchase Agreement (the "Agreement") between Cyclacel's former interim chief executive officer David Lazar ("Seller") and Datuk Dr. Doris Wong Sing Ee ("Purchaser"), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the "Series C") and such number of the 2,100,000 shares of Series D Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the "Series D") held by Seller so that Purchaser owns 70% of the issued and outstanding shares of Cyclacel, which resulted in the issuance of 1,745,262 shares of Series D (collectively, the Series C and Series D, the "Securities"). The transaction contemplated by the Agreement closed on February 26, 2025 (the "Closing Date") at which point Purchaser purchased and succeeded to all of Seller's rights and interests under the securities purchase agreement between Seller and Cyclacel dated January 2, 2025.
Purchaser acquired the Securities for a total consideration of $6,300,000 (the "Purchase Price") less a holdback amount of $100,000 (the "Holdback Amount") to the escrow agent. The Purchase Price included a cash brokerage fee of $800,000. The Holdback Amount will be held by Purchaser for 120 days from the Closing Date to satisfy any indemnity and other agreed upon claims and expenses.
On the Closing Date, Seller issued written notice to Cyclacel to exercise the conversion rights related to the Series C and Series D shares into the common stock, par value $0.001 per share (the "Common Stock") of Cyclacel registered in Purchaser's name, as follows: (i) 1,000,000 shares of Series C into 2,650,000 shares of Common Stock and (ii) 1,745,262 shares of Series D into 191,978,820 shares of Common Stock. As of the Closing Date, Purchaser has become the new controlling shareholder of Cyclacel.
At the same time, David Lazar resigned as interim chief executive officer and secretary and Datuk Dr. Doris Wong Sing Ee was elected as Chief Executive Officer and Executive Director of Cyclacel. Cyclacel also announced the appointment of Kiu Cu Seng as Executive Director, Secretary and Chief Financial Officer and, in such role, he will serve as the Company's co-principal financial officer and co-principal accounting officer along with David Lazar until the effective date of his resignation on the earlier of the filing date of the Company's annual report on Form 10-K for the fiscal year ended December 31, 2024 or March 31, 2025.

Management

CYCC

CYCCP

Cyclacel Pharmaceuticals Announces Leadership Change After $6.3M Share Purchase; Datuk Dr. Doris Wong Sing Ee Acquires 70% Stake And Becomes CEO; David Lazar Resigns As Interim CEO, Kiu Cu Seng Appointed CFO

GoodRx Holdings Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) reported fourth-quarter revenue of $198.6 million, up slightly by 1% year over year, missing the management guidance of around $200 million and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $199.75 million</a>.
Fiscal year sales of $792.3 million came in below the guidance of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41800510/goodrx-reports-third-quarter-2024-results" rel="noreferrer noopener">around $794 million</a>.
The company reported adjusted EPS of 9 cents, up from 8 cents a year ago, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44000935/goodrx-reports-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">missing the consensus of 10 cents</a>.
Q4 prescription transactions revenue increased 0.8% to&nbsp;$144.9 million. 2024 prescription transactions revenue increased 5% to $577.5 million, driven by an organic 7% increase in Monthly Active Consumers, including the expansion of an integrated savings program.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42349122/how-much-did-americans-overspend-on-weight-loss-medications-in-2024-goodrx-reveals" rel="noreferrer noopener">How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals</a>
GoodRx exited the fourth quarter of 2024 with over 7 million prescription-related consumers using GoodRx across prescription transactions and subscription offerings. Monthly active consumers were 6.6 million, with subscription plans of 684k.
The 2024 subscription revenue decreased by 8% to $86.5 million, primarily driven by a decrease in subscription plans due to the sunset of the partnership subscription program, Kroger Savings Club. In Q4, subscription revenue fell 10.7% to $20.68 million.
Q4 Pharma manufacturer solutions revenue jumped from $24.4 million to $28.1 million. 2024 Pharma manufacturer solutions revenue increased 26% to $107.2 million, primarily driven by organic growth as the company expands market penetration with pharma manufacturers and other customers.
Adjusted EBITDA reached $67.08 million in Q4 and $260.2 million in 2024.
Guidance: The prescription savings platform expects a fiscal year 2025 revenue outlook of $810 million—$840 million, up 2%—6% versus the consensus of $825.57 million, with adjusted EBITDA of $270 million—$286 million.
GoodRx forecasts first-quarter 2025 revenue of $201 million—$205 million, up 2%-4%, versus consensus of $202.53 million, with an adjusted EBITDA margin of about 33%.
Price Action: GDRX stock is up 4.6% at $5.12 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44006958/bath-body-works-posts-4-sales-decline-in-q4-stock-plunges" target="_blank" rel="noreferrer noopener">Bath &amp; Body Works&#8217; Stock Slips As Soft Outlook Overshadows Q4 Earnings Beat: Details</a></li>
</ul>
Photo: Shutterstock

Guidance

Health Care

GDRX

GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales

DA Davidson analyst Linda Bolton Weiser maintains Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) with a Neutral and lowers the price target from $38 to $36.

USNA

DA Davidson Maintains Neutral on Usana Health Sciences, Lowers Price Target to $36

JP Morgan analyst Pinjalim Bora maintained an Underweight rating on C3.ai, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) with a <a target="_blank" href="https://www.benzinga.com/quote/AI/analyst-ratings" rel="noreferrer noopener">price target of $27, down from $28</a>.
C3.ai reported a <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43992114/c3ai-q3-earnings-highlights-revenue-beat-eps-beat-significant-milestones-achieved" rel="noreferrer noopener">third-quarter revenue</a> of $98.8 million, up 26%. The revenue total beat a Street consensus estimate of $98.1 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/44008324/echostar-q4-3-97-billion-revenue-narrows-pay-tv-subscriber-losses-focuses-on-high-quality-users-wireless-growth" rel="noreferrer noopener">EchoStar Q4: $3.97 Billion Revenue, Narrows Pay-TV Subscriber Losses, Focuses On High-Quality Users, Wireless Growth</a>
The company had an adjusted net loss of 12 cents per share, which beat a street consensus estimate of 25 cents per share.
C3.ai expects fourth-quarter revenue of $103.6 million-$113.6 million, versus the consensus estimate of $108.6 million.
Bora updated his AI model to include the third quarter of fiscal 2025 results. The price target is based on ~7 times EV/calendar 2026E revenue (unchanged) relative to infrastructure software companies growing FTM revenue over 20%, trading at ~10x EV/calendar 2026E revenue.
The lower price target reflects subpar core growth, adjusted for demo licenses.
The analyst noted that AI should trade at a significant discount to this group as growth is similar but at a much smaller scale for AI. Also, AI is extremely unprofitable compared to the comps.
While AI will likely grow FTM revenue at a comparable growth level (23% versus 24% for the comps&#8217; median), AI is 80% smaller than the median scale of the comp group.
Additionally, AI will likely have (14%) FTM free cash flow margin driving a growth plus margin profile of 9%, versus comps at +22% Unlevered Free Cash Flow (UFCF) margin driving a growth plus margin of +46%. Furthermore, the calendar 2025 adjusted operating margin for AI will likely be (24%) versus comps at +15%.
Price Action: AI stock is down 6.24% at $25.05 at last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/44007299/warner-bros-q4-earnings" target="_blank" rel="noreferrer noopener">Warner Bros Q4 Earnings: Studios Revenues Grow 16%, Max Subscribers Surge, Eyes 150 Million Subscribers By 2026</a></li>
</ul>
Photo via Shutterstock

Tech

C3.ai Sees Stronger Revenue But Analyst Concerned Over Profitability And Scale

Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) shares are trading higher on Thursday. On Wednesday, the company reported fourth-quarter losses of 34 cents per share. This missed the analyst consensus estimate for a loss of 20 cents and revenue of $55,000, beating the <a href="https://www.benzinga.com/news/earnings/25/02/43993466/joby-aviation-stock-climbs-after-q4-results-heres-why" target="_blank" rel="noreferrer noopener">analyst consensus estimate of $45,800</a>.
JPMorgan analyst Bill Peterson cut the price forecast to $5.00 from $6.00 while <a href="https://www.benzinga.com/quote/JOBY/analyst-ratings" target="_blank" rel="noreferrer noopener">maintaining an Underweight rating</a>.
The analyst&#8217;s bearish stance reflects the expected higher cash burn outlook and delays in aircraft deliveries.
Notably, the analyst writes that cash burn will rise as Joby expands its manufacturing capabilities to support increased production rates for parts.
Also, Peterson says that further delays are expected for the commercial launch in Dubai, depending on the progress of GCAA verification and infrastructure development in the UAE.
A similar situation may unfold in the U.S. TIA flight testing will begin within the next year. This could push a small-scale commercial launch to the second half of 2026, adds the analyst.
Meanwhile, the analyst says that the defense sector remains a key market opportunity, with spending expected to rise further in 2025/2026.
While it is still too early to determine the full scope of the defense market opportunity, its potential will likely depend on specific applications, such as logistics versus combat operations, adds the analyst.
Given the capital-intensive nature of the business, the company will likely pursue additional funding opportunities. Spending is anticipated to accelerate further as it moves toward commercialization, adds the analyst.
Investors can gain exposure to Joby through two exchange-traded funds, or ETFs: 
<ul>
<li>WisdomTree Trust WisdomTree Battery Value Chain and Innovation Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/WBAT#BATS">WBAT</a>)</li>
<li>ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>).</li>
</ul>
Price Action: Joby Aviation shares are up 4.64% at $7.01 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/02/43946240/rocket-lab-kratos-archer-aviation-and-more-earnings-this-week-could-have-a-big-impact-on-cathie-woods-ark-etfs" target="_blank" rel="noreferrer noopener">Rocket Lab, Kratos, Archer Aviation And More Earnings This Week Could Have A Big Impact On Cathie Wood&#8217;s Ark ETFs</a></li>
</ul>
Image: Courtesy of Joby Aviation, Inc.

Mid Cap

ARKX

JOBY

WBAT

Joby Aviation Posts Mixed Q4 Results, Beware Of Higher Cash Burn And Aircraft Delivery Delays: Analyst

Macquarie analyst Paul Golding maintains Planet Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) with a Neutral and lowers the price target from $99 to $95.

PLNT

Macquarie Maintains Neutral on Planet Fitness, Lowers Price Target to $95

ACMR, ALAB, AMAT, AMBA, AMD, AMKR, AOSL, ARM, ARQQ, ASML, ASX, ATO, CAMT, CRDO, ENTG, FORM, HIMX, ICHR, INTC, KLAC, KLIC, LAES, LRCX, MKSI, MTSI, MU, MXL, NN, NVDA, NVMI, NVTS, ONDS, ONTO, QUIK, RGTI, RMBS, SITM, SKYT, SMH, SMTC, SOXX, STM, TSEM, TSM, UCTT, VUZI, WOLF

ALAB

AMAT

AMBA

AMCR

AMKR

AOSL

ARQQ

ASML

CAMT

CRDO

ENTG

FORM

HIMX

ICHR

KLAC

KLIC

LRCX

MKSI

MTSI

NVMI

NVTS

ONDS

ONTO

QUIK

RGTI

RMBS

SITM

SKYT

SMTC

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

TSEM

UCTT

VUZI

Shares of semiconductor companies are trading lower in sympathy with Nvidia, which reversed amid a possible selloff after reporting Q4 financial results.

Project awards represent approximately $1.25 billion in customer-focused investments for FirstEnergy Transmission and $46 million for other FirstEnergy subsidiaries
AKRON, Ohio, Feb. 27, 2025 /PRNewswire/ -- FirstEnergy Transmission LLC (FET), jointly owned by FirstEnergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>) and Brookfield Super-Core Infrastructure Partners, has been awarded multiple transmission projects by grid operator PJM Interconnection&nbsp;that are designed to strengthen the electric grid and support regional economic growth. The awards include projects that FET will develop through the Valley Link Transmission Company LLC joint venture with Dominion Energy and American Electric Power Company, as well as projects that FET will develop individually within its service territory.
In total, FET will invest approximately $1.25 billion in the approved customer-focused transmission projects. In addition,&nbsp;FirstEnergy's Potomac Edison, JCP&amp;L and Keystone Appalachian Transmission Company (KATCo)&nbsp;subsidiaries&nbsp;will invest $46 million upgrading equipment at substations and reconfiguring transmission lines in Maryland, New Jersey and Pennsylvania.
The projects were proposed through PJM's 2024 Regional Transmission Expansion Plan (RTEP) open window process and were approved Feb. 26 by the PJM Board of Managers. PJM is the regional transmission organization that coordinates the transportation of wholesale electricity across the 13-state region that includes FirstEnergy's service territory.

Contracts

FirstEnergy Awarded Projects By PJM Interconnection To Enhance Reliability And Address Rising Customer Demand; $1.25B Grid Enhancement Projects, $46M Upgrades For Subsidiaries

Press Releases

HUMBL Announces Purchase of HUMBL Financial by Avrio, to Drive a Range of Financial Products and Services into the Global Markets

Minnesota Myth of the AFL Signs Merchandising Deal with HUMBL Authentics

HUMBL Reduces Stockholders' Deficit by over $33 Million Since the End of Calendar Year 2022

HUMBL and the Oregon BlackBears Deliver Innovative Digital Ticketing Program

HUMBL Issued U.S. Patent for System and Method for Transferring Currency Using Blockchain

HUMBL Completes Stock Purchase Agreement with Ybyra Capital and Sale of its Assets for $20,000,000 to WSCG, Inc.

HUMBL

In 2023, top executives in the cannabis industry continued to play a pivotal role in shaping the future of the rapidly growing market.



These executives championed sustainability, social responsibility and inclusive business practices on the path to creating a more diverse and equitable cannabis industry. Their leadership contributed to the normalization of cannabis, driving mainstream acceptance and reshaping public perceptions.



Humble &amp; Fume Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/HMBL#CSE">HMBL</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/HUMBF#OTCQX">HUMBF</a>), kicked off 2023 by <a href="https://www.benzinga.com/markets/cannabis/23/01/30406998/key-marijuana-executive-changes-you-should-know-about-this-company-got-a-new-ceo-more-news">naming Jakob Ripshtein</a> as its new CEO. He replaced Joel Toguri. Under Ripshtein's guidance, the company reported <a href="https://www.benzinga.com/markets/cannabis/23/10/35463550/canadas-top-weed-accessory-distributor-will-ramp-up-in-california-reports-2023-sales-uptick">positive financial results</a> for the full year of 2023. The company plans to intensify its efforts in the California cannabis sector going forward.



In February, cannabis social media platform WeedTube <a href="https://www.benzinga.com/markets/cannabis/23/02/31022325/keeping-up-with-cannabis-key-industry-and-executive-changes-you-should-know-about">elected Maggie Adair</a> as its new CEO. Adair, a graduate of George Washington University with degrees in Communications and Political Management, has had a successful career in the political realm of Washington D.C., working for top political officials in media, campaigns, <a href="https://www.benzinga.com/markets/cannabis/23/02/30989888/meet-the-new-ceo-of-weedtube-a-political-powerhouse-with-a-passion-for-cannabis">and the tech field.</a>



Cannabis multi-state operator MariMed.'s (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTCQX">MRMD</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#CSE">MRMD</a>) board of directors tapped Edward Gildea to serve as their chairman and <a href="https://www.benzinga.com/markets/cannabis/23/03/31195566/latest-executive-changes-in-marijuana-industry-new-appointments-more">Jon Levine as CEO in March.</a> Levine, the company&#8217;s co-founder and president, who was one of the speakers at April&#8217;s Cannabis Capital Conference. Levin took over as interim CEO after the untimely death of co-founder, chairman and CEO Bob Fireman. The company, one of analyst's favorite stocks closed a $58.7 million secured credit facility with a U.S. chartered bank in November and is now <a href="https://www.benzinga.com/markets/cannabis/23/11/35874567/one-of-analysts-favorite-marijuana-stocks-says-farewell-to-debt-closes-58-7m-refinancing-deal">expected to "generate significant cash savings."</a>



July was a busy month in the cannabis sector with <a href="https://www.benzinga.com/markets/cannabis/23/07/33280078/top-talent-to-lead-two-new-us-marijuana-markets-and-latest-key-hires-in-cannabis-industry">several companies naming new CEOs:</a>



<ul>
<li>Sabas Carrillo agreed to lead the California-based cannabis producer Unrivaled Brands, Inc (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/UNRV#OTCQB">UNRV</a>);</li>



<li>iAnthus Capital Holdings, Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/IAN#CSE">IAN</a>) (OTCPK: ITHUF) appointed Richard Proud as CEO and the board&#8217;s director;</li>



<li>PharmaCielo Ltd. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/PCLOF#OTCQX">PCLOF</a>) (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/PCLO#TSXV">PCLO</a>) the Canadian parent of Colombia&#8217;s premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. named Marc Lustig as chairman and CEO;</li>



<li>MedMen Enterprises Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/MMEN#CSE">MMEN</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/MMNFF#OTCQX">MMNFF</a>) appointed Ellen Deutsch as CEO; and</li>



<li>Flora Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) tapped <a href="https://www.benzinga.com/markets/cannabis/23/07/33119512/leadership-shake-ups-across-several-weed-companies-who-got-the-top-jobs">Clifford Starke to serve as CEO.</a></li>
</ul>



In September, Charlotte&#8217;s Web (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTCQX">CWBHF</a>) (TSX: CWEB) tapped William Morachnick as CEO, succeeding CEO Jacques Tortoroli, who resigned from <a href="https://www.benzinga.com/markets/cannabis/23/09/34534219/former-reynolds-american-executive-joins-charlottes-web-as-new-ceo">his roles at the Colorado-based company.</a>



Cannabis veteran executive Gary Santo agreed to assume the CEO role at RX Green Technologies in October, <a href="https://www.benzinga.com/markets/cannabis/23/10/35289402/marijuana-veteran-gary-santo-to-lead-denver-maker-of-cannabis-cultivation-inputs-and-services">replacing Wes Matelich</a>. Cannabis-focused commercial real estate finance company AFC Gamma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFCG#NASDAQ">AFCG</a>) wrapped up the month by tapping industry veteran <a href="https://www.benzinga.com/markets/cannabis/23/10/35491822/cannabis-lender-taps-industry-veteran-as-ceo-to-gain-in-house-operating-expertise">Daniel Neville as its new CEO.</a>



In November, the governmental cannabis retail monopoly in the Canadian province of Quebec, the Société québécoise du cannabis (SQDC) named<a href="https://www.benzinga.com/markets/cannabis/23/11/35560804/woman-takes-helm-of-quebecs-cannabis-retail-monopoly-and-more-industry-changes"> Suzanne Bergeron</a> as its new president and CEO. Cannabis vape producer The Blinc Group promoted Pete Sahani, the company's COO since 2022, to <a href="https://www.benzinga.com/markets/cannabis/23/11/36003747/cannabis-industrys-new-mavericks-two-companies-introduce-fresh-leadership">CEO a month ago.</a>



This week, Kaival Brands Innovations Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAVL#NASDAQ">KAVL</a>) announced that it has expanded the role of Barry M. Hopkins, executive chairman, to include the positions of interim CEO and president.



Missed the first wave of cannabis investments? Don't make that mistake again. Experts believe <a target="_blank" href="https://marketfy.com/item/420investor/" rel="noreferrer noopener">cannabis stocks have found their floor</a> and are now poised for unprecedented growth. Join <a target="_blank" href="https://marketfy.com/item/420investor/" rel="noreferrer noopener">Benzinga PotProfits</a>. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising <a target="_blank" href="https://marketfy.com/item/420investor/#overview-page" rel="noreferrer noopener">cannabis stocks poised for growth</a>, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities! &nbsp;Just this year, the PotProfits <a target="_blank" href="https://marketfy.com/item/420investor/#overview-page" rel="noreferrer noopener">portfolio</a> has seen smoking-hot gains like:



<ul>
<li>&nbsp;47.10% with $GTBIF</li>



<li>&nbsp;40.23% with $TCNNF</li>



<li>&nbsp;21.50% with $VFF</li>
</ul>



&nbsp;But here's the kicker: Michael is about to release his <a target="_blank" href="https://marketfy.com/item/420investor/#overview-page" rel="noreferrer noopener">next potential winners</a>, and he's chomping at the bit to share these ticker symbols with you ASAP.



Don't miss out on the <a target="_blank" href="https://marketfy.com/item/420investor/#overview-page" rel="noreferrer noopener">green rush</a>!

HUMBL (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HMBL#OTC">HMBL</a>) has outperformed the market over the past 5 years by 234.07% on an annualized basis producing an average annual return of 243.22%. Currently, HUMBL has a market capitalization of $39.29 million. 
Buying $100 In HMBL: If an investor had bought $100 of HMBL stock 5 years ago, it would be worth $4,762.50 today based on a price of $0.02 for HMBL at the time of writing.
<h3>HUMBL's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2023/1675884911_0.png" alt="comp_fig" />

Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Dividends

Here's How Much $100 Invested In HUMBL 5 Years Ago Would Be Worth Today

Comments

HUMBL Stock News

News

Latest HUMBL Stock News | OTC:HMBL | Benzinga

Friday, December 29, 2023

Wednesday, February 08, 2023

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga